Titan Pharmaceuticals Inc (TTNP)
3.92
-0.11
(-2.73%)
USD |
NASDAQ |
Nov 05, 09:56
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 3.584M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -52.33% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 0.8975 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.91% |
Profile
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. |
URL | https://www.titanpharm.com |
Investor Relations URL | N/A |
HQ State/Province | California |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Blend |
Next Earnings Release | Nov. 14, 2024 (est.) |
Last Earnings Release | Aug. 15, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. |
URL | https://www.titanpharm.com |
Investor Relations URL | N/A |
HQ State/Province | California |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Blend |
Next Earnings Release | Nov. 14, 2024 (est.) |
Last Earnings Release | Aug. 15, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |